| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.suvenpharm.com | |
| Market Cap | 13,523.76 Cr. | |
| Enterprise Value(EV) | 13,524.91 Cr. | 2023-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 16.67 | Trailing Twelve Months Ending 2023-06 |
| Price-Earning Ratio (PE) | 31.86 | Trailing Twelve Months Ending 2023-06 |
| Industry PE | 37.33 | Trailing Twelve Months Ending 2023-06 |
| Book Value / Share | 72.90 | Trailing Twelve Months Ending 2023-06 |
| Price to Book Value | 7.28 | Calculated using Price: 531.00 |
| Dividend Yield | 0.94 | Period Ending 2022-03 |
| No. of Shares Subscribed | 25.46 Cr. | 254,564,956 Shares |
| FaceValue | 1 | |
| About Suven Pharmaceuticals Ltd. | ||
| The company is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry. | ||
| 1 Day |
|
+0.72% |
| 1 Week |
|
-4.19% |
| 1 Month |
|
+2.63% |
| 3 Month |
|
+9.07% |
| 6 Month |
|
+12.50% |
| 1 Year |
|
+21.68% |
| 2 Year |
|
-1.78% |
| 5 Year |
|
|
| 10 Year |
|
| 4 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 18.92 | 37.80 | 30.47 | 30.48 | |
| Return on Capital Employed (%) | 23.87 | 44.55 | 36.19 | 43.13 | |
| Return on Assets (%) | 13.39 | 25.50 | 21.52 | 23.30 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
| Shh. Funds | 590 | 845 | 1,181 | 1,527 | 1,735 | |
| Non Curr. Liab. | 35 | 128 | 74 | 92 | 72 | |
| Curr. Liab. | 191 | 320 | 322 | 348 | 159 | |
| Minority Int. | ||||||
| Equity & Liab. | 816 | 1,292 | 1,576 | 1,967 | 1,966 | |
| Non Curr. Assets | 393 | 781 | 910 | 702 | 955 | |
| Curr. Assets | 423 | 511 | 667 | 1,265 | 1,011 | |
| Misc. Exp. not W/O | ||||||
| Total Assets | 816 | 1,292 | 1,576 | 1,967 | 1,966 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-06 Rs. Cr. TTM |
| Net Sales | 378 | 834 | 1,010 | 1,320 | 1,349 | |
| Other Income | 1 | 18 | 14 | 92 | 46 | |
| Total Income | 378 | 852 | 1,024 | 1,413 | 1,395 | |
| Total Expenditure | -206 | -449 | -567 | -739 | -766 | |
| PBIDT | 172 | 403 | 457 | 674 | 629 | |
| Interest | -3 | -23 | -12 | -9 | -5 | |
| Depreciation | -12 | -24 | -32 | -39 | -49 | |
| Taxation | -49 | -88 | -105 | -214 | -150 | |
| Exceptional Items | ||||||
| PAT | 109 | 269 | 309 | 413 | 424 | |
| Minority Interest | ||||||
| Share Associate | 48 | 54 | 41 | |||
| Other Related Items | ||||||
| Consolidated Net Profit | 109 | 317 | 362 | 454 | 424 | |
| Adjusted EPS | 12 | 14 | 18 | 17 |
| Particulars | 4 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 50 | 407 | 383 | 330 | |
| Cash Fr. Inv. | -65 | -413 | -311 | -136 | |
| Cash Fr. Finan. | 26 | 7 | -76 | -156 | |
| Net Change | 11 | 1 | -5 | 37 | |
| Cash & Cash Eqvt | 11 | 12 | 7 | 45 |
|
Tue, 26 Sep 2023
Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 We are pleased to inform you that the Company has received an intimation on September 25 2023 that the Department of Pharmaceuticals Ministry of Chemicals and Fertilizers has granted its approval for acquisition of upto 76.1% shareholding in the Company by M/s. Berhyanda Limited Cyprus (Acquirer) by way of transfer of 12 75 37 043 equity shares aggregating to 50.1% of shareholding in the company from promoters of the Company and acquisition of up to 6 61 86 889 equity shares aggregating to 26% of shareholing in the Company from public shareholders through mandatory open offer. The aggregate foreign investment including investment from other foreign investors may be up to 90.1% shareholding in the Company. |
|
Mon, 04 Sep 2023
Intimation Of Extension Of Time For Holding Annual General Meeting (AGM) We wish to inform you that the Company Suven Pharmaceuticals Limited filed an applicaiton before the Registrar of Companies Hyderabad for an extension of holding Annual General Meeting (AGM) for the Financial Year 2022-23 which is due to be held on or before 30/09/2023 pursuant to the provisions of section 96(1) of the Companies Act 2023.The Registrar of Companies Hyderabad has approved the application and extended the date of AGM for 3 (three) months i.e. upto December 31 2023. |
|
Mon, 14 Aug 2023
Announcement under Regulation 30 (LODR)-Earnings Call Transcript Please find enclosed the transcript of the earnings conference call for the quarter ended Juen 30 2023. |
| Tue, 26 Sep 2023 |
Higher Trade Quantity
|
Opening at Low
|
Close Within 52 Week High Zone
|
MFI Above 80
|
| Mon, 25 Sep 2023 |
Close Crossing Last Week Low
|
Equities
M.F.
Sectors
StockEdge Social